The Establishment of Biomarkers in Patients with Nocturnal Enuresis: Serum Copeptin and Urinary Aquaporin-2
Not Applicable
- Conditions
- Monosymptomatic Nocturnal Enuresis
- Registration Number
- JPRN-UMIN000016915
- Lead Sponsor
- Department of Pediatrics, Juntendo University Graduated School of Medicine
- Brief Summary
1 Urinary aquaporin 2 appears to be a biomarker of desmopressin treatment effectiveness during the Treatment of Monosymptomatic Nocturnal Enuresis. 2 Plasma copeptin levels before treatment are predictive of desmopressin response.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with underlying pathologic conditions such as renal, endocrine, metabolic and neurological disorders resulted in nocturnal enuresis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum Copeptin and urinary Aquaporin-2 levels: before the treatment, 4 and 8 weeks after the treatment, and after the treatment
- Secondary Outcome Measures
Name Time Method rine volume during the night, urinary osmolarity and creatinine before and after sleep : before the treatment, 4 and 8 weeks after the treatment, and after the treatment